Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma

References

• Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006 Oct 1;24(28):4539–4544.
   PubMed Web of Science ®Google Scholar
• Oronsky B, Reid TR, Oronsky A, et al. What’s New in SCLC? A Review. Neoplasia. 2017;19(10):842–847.
   PubMed Web of Science ®Google Scholar
• Altekruse SF, Kosary CL, Krapcho M, et al. SEER cancer statistics review. National Cancer Institute; 1975–2007. Ref Type: Internet Communication. [cited 2020 Feb 11]. Available from: http://seer.cancer.gov/csr/1975_2007/2010
   Google Scholar
• Kazarian M, Laird-Offringa IA. Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy. Mol Cancer. 2011;10:33.
   PubMed Web of Science ®Google Scholar
• Waqar SN, Morgensztern D. Treatment advances in small cell lung cancer (SCLC). Pharmacol Ther. 2017 Dec;180:16–23.
   PubMed Web of Science ®Google Scholar
• Meuwissen R, Linn SC, Linnoila RI, et al. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell. 2003;4:181–189.
   PubMed Web of Science ®Google Scholar
• Puglisi M, Dolly S, Faria A, et al. Treatment options for small cell lung cancer—do we have more choice? Br J Cancer. 2010;102:629–638.
   PubMed Web of Science ®Google Scholar
• Chan BA, Coward JIG. Chemotherapy advances in small-cell lung cancer. J Thorac Dis. 2013;5(Suppl 5):S565–S578.
   PubMedGoogle Scholar
• Mattern MR, Mong SM, Bartus HF, et al. Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Cancer Res. 1987;47:1793–1798.
   PubMed Web of Science ®Google Scholar
• Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol. 1997 May;15(5):2090–2096.
   PubMedGoogle Scholar
• Hann CL, Rudin CM. Fast, hungry and unstable: finding the Achilles’ heel of small-cell lung cancer. Trends Mol Med. 2007 Apr;13(4):150–157. Epub 2007 Feb 26.
   PubMed Web of Science ®Google Scholar
• Davies AM, Evans WK, Mackay JA, et al. Treatment of recurrent small cell lung cancer. Hematol Oncol Clin North Am. 2004;18(2):387–416.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Crowley J, Van Houtte P, et al. International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol. 2007 Dec;2(12):1067–1077.
   PubMed Web of Science ®Google Scholar
• Cabrales P. RRx-001 acts as a dual small molecule checkpoint inhibitor by downregulating CD47 on cancer cells and SIRP-α on Monocytes/ Macrophages. Transl Oncol. 2019;12(4):626–632.
   PubMed Web of Science ®Google Scholar
• Sharma Das D, Ray A, Das A, et al. A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells. Leukemia. 2016 Nov; ; 30(11):2187-2197. DOI: 10.1038/leu.2016.96.
   PubMed Web of Science ®Google Scholar
• Oronsky B, Scicinski J, Cabrales P, et al. RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors. Clin Epigenetics. 2016 May 11;8:53.
   PubMed Web of Science ®Google Scholar
• Oronsky B, Reid TR, Larson C, et al. RRx-001 protects against cisplatin-induced toxicities. J Cancer Res Clin Oncol. 2017 Sep;143(9):1671–1677.
   PubMed Web of Science ®Google Scholar
• Kim MM, Parmar H, Cao Y, et al. Whole brain radiotherapy and RRx-001: two partial responses in radioresistant melanoma brain metastases from a Phase I/II clinical trial: A TITE-CRM Phase I/II clinical trial. Transl Oncol. 2016 Apr;9(2):108–113.
   PubMed Web of Science ®Google Scholar
• Kim MM, Parmar H, Cao Y, et al. Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases. Neuro Oncol. 2016 Mar;18(3):455–456.
   PubMed Web of Science ®Google Scholar
• Carter CA, Oronsky BT, Caroen SZ, et al. Partial response to platinum doublets in refractory EGFR-positive non-small cell lung cancer patients after RRx-001: evidence of episensitization. Case Rep Oncol. 2016 Jan 28;9(1):62–67.
   PubMed Web of Science ®Google Scholar
• Reid T, Dad S, Korn R, et al. Two case reports of resensitization to previous chemotherapy with the novel hypoxia-activated hypomethylating anticancer agent RRx-001 in metastatic colorectal cancer patients. Case Rep Oncol. 2014 Jan 24;7(1):79–85.
   PubMedGoogle Scholar
• Oronsky B, Paulmurugan R, Foygel K, et al. RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials. Expert Opin Investig Drugs. 2017 Jan;26(1):109–119.
   PubMed Web of Science ®Google Scholar
• He C, Carter AB. The metabolic prospective and redox regulation of macrophage polarization. J Clin Cell Immunol. 2015 Dec 6;(6):371. Epub 2015 Dec; ;6(6):371.
   PubMedGoogle Scholar
• Kreuz S, Fischle W. Oxidative stress signaling to chromatin in health and disease. Epigenomics. 2016 Jun;8(6):843–862. Epub 2016 Jun 20.
   PubMed Web of Science ®Google Scholar
• Das DS, Ray A, Das A, et al. A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells. Leukemia. 2016 Nov;30(11):2187–2197.
   PubMed Web of Science ®Google Scholar
• Riabov V, Gudima A, Wang N, et al. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol. 2014 Mar 5;5:75.
   PubMed Web of Science ®Google Scholar
• Oronsky B, Reid T, Oronsky A, et al. RRx-001 is A c-myc inhibitor that targets cancer stem cells. Accepted for publication. Oncotarget.2018 May 4;9(34):23439-23442. doi: 10.18632/oncotarget.25211.
   Google Scholar
• Sainz B, Carron E, Vallespinós M, et al. Cancer stem cells and macrophages: implications in tumor biology and therapeutic strategies. Mediators Inflamm. 2016;2016:9012369.
   PubMed Web of Science ®Google Scholar
• Carter CA, Schmitz B, Peterson PG, et al. Immune reactivity and pseudoprogression or tumor flare in a serially biopsied neuroendocrine patient treated with the epigenetic agent RRx-001. Case Rep Oncol. 2016 Mar 10;9(1):164–170.
   PubMed Web of Science ®Google Scholar
• Zhao H, Ning S, Nolley R, et al. The immunomodulatory anticancer agent RRx-001 induces a vaccine-like interferon response through epigenetic induction of viral mimicry. AACR Annual Meeting; April 1-5; Washington, DC. 2017.
   Google Scholar
• Chanmee T, Ontong P, Konno K, et al. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel). 2014;6(3):1670–1690.
   PubMed Web of Science ®Google Scholar
• Reid T, Oronsky B, Scicinski J, et al. Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. Lancet Oncol. 2015 Sep;16(9):1133–1142.
   PubMed Web of Science ®Google Scholar
• Oronsky B, Oronsky N, Scicinski J, et al. Rewriting the epigenetic code for tumor resensitization: a review. Transl Oncol. 2014 Oct 24;7(5):626–631.
   PubMed Web of Science ®Google Scholar
• Strauss J, Figg W. Epigenetic approaches to overcoming chemotherapy resistance. Lancet Oncol. 2015 Sep;16(9):1013–1015.
   PubMed Web of Science ®Google Scholar
• Reid T, Knox S, Ning S, et al. Resensitization to previous chemotherapy with the novel hypomethylating anticancer agent RRx-001. 16th International Symposium on Anti-Angiogenic Therapy; Feb 6 – 8; La Jolla. 2014.
   Google Scholar
• Morgensztern D, Rose M, Waqar SN, et al. RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer. Br J Cancer. 2019 Jul;121(3):211-217.
   PubMed Web of Science ®Google Scholar
• Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66:605–612.
   PubMed Web of Science ®Google Scholar
• Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196:254–265.
   PubMed Web of Science ®Google Scholar
• EpicentRx. Unpublished data.
   Google Scholar
• Huang A, Zhang B, Wang B, et al. Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. Cancer Immunol Immunother. 2013 Sep;62(9):1439–1451.
   PubMed Web of Science ®Google Scholar
• Yazawa T, Kamma H, Fujiwara M, et al. Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer. J Pathol. 1999;187:191–199.
   PubMed Web of Science ®Google Scholar
• Auffray C, Fogg D, Garfa M, et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science. 2007;317:666–670.
   PubMed Web of Science ®Google Scholar
• Deshmane SL, Kremlev S, Amini S, et al. Monocyte Chemoattractant Protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29(6):313–326.
   PubMed Web of Science ®Google Scholar